Novartis sues Biocon over patent


Accusing India drug maker Biocon of infringing on its diabetes drug Galvus patent, Novartis (NVS) goes to Delhi's High Court in an attempt to stop the firm from launching a generic vildagliptin.

The court ruled on March 28 that Biocon cannot proceed until the next court hearing.

India has been a battleground for Big Pharma because local authorities have overruled patents and instituted price cuts in an effort to expand access to medicines. 70% of Indians live on less than $2/day.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs